Plasma Endocan As a Predictor of Cardiovascular Event in Patients with End-Stage Renal Disease on Hemodialysis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Dec 23

PMID 33352837

Citations 5

Authors

Jin Sug Kim

Gang Jee Ko

Yang Gyun Kim

So Young Lee

Dong Young Lee

Kyung Hwan Jeong

Sang Ho Lee

Affiliations

Soon will be listed here.

Abstract

Endocan, a potential biomarker of endothelial dysfunction, is associated with increased cardiovascular risk. We investigated the utility of plasma endocan for predicting cardiovascular risk in end-stage renal disease (ESRD) patients undergoing hemodialysis. Of the 452 patients in the K-cohort, 354 with available plasma endocan levels were enrolled. The correlation between plasma endocan levels and the clinical characteristics of a study population were analyzed. We divided patients into two groups, according to plasma endocan levels, and investigated the predictive value of endocan for the occurrence of cardiovascular events. In a multiple linear regression analysis, plasma endocan levels were positively correlated with previous cardiovascular events and negatively correlated with body mass index, albumin, and triglyceride. Patients with higher plasma endocan levels experienced more frequent cardiovascular events than those with lower plasma endocan levels (12.9% in the lower group vs. 22.7% in the higher group, = 0.016). Cox proportional hazard models showed that higher plasma endocan levels were an independent predictor of cardiovascular events in ESRD patients on hemodialysis ((hazard ration) HR 1.949, 95% (confidence interval) CI 1.144-3.319, = 0.014). Our results suggest that plasma endocan level might be a useful biomarker for predicting cardiovascular events in ESRD patients on hemodialysis.

Citing Articles

Serum Endocan Is a Risk Factor for Aortic Stiffness in Patients Undergoing Maintenance Hemodialysis.

Wu T, Wang C, Lai Y, Kuo C, Lin Y, Hsu B Medicina (Kaunas). 2024; 60(6).

PMID: 38929601 PMC: 11205908. DOI: 10.3390/medicina60060984.

Endocan as a Potential Marker for Predicting All-Cause Mortality in Hemodialysis Patients.

Lin J, Hsu B, Wang C, Tsai J J Clin Med. 2023; 12(23).

PMID: 38068479 PMC: 10706971. DOI: 10.3390/jcm12237427.

High circulating endocan in chronic kidney disease? A systematic review and meta-analysis.

Khalaji A, Behnoush A, Kia Y, Alehossein P, Bahiraie P PLoS One. 2023; 18(8):e0289710.

PMID: 37556458 PMC: 10411816. DOI: 10.1371/journal.pone.0289710.

Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis.

Khalaji A, Behnoush A, Saeedian B, Khanmohammadi S, Shokri Varniab Z, Peiman S Diabetol Metab Syndr. 2023; 15(1):102.

PMID: 37189201 PMC: 10186635. DOI: 10.1186/s13098-023-01076-z.

Elevated Circulating Endocan Levels Are Associated with Increased Levels of Endothelial and Inflammation Factors in Postprandial Lipemia.

Yaman S, Balaban Yucesan F, Orem C, Vanizor Kural B, Orem A J Clin Med. 2023; 12(4).

PMID: 36835804 PMC: 9966245. DOI: 10.3390/jcm12041267.

References

Mihajlovic D, Lendak D, Brkic S, Draskovic B, Mitic G, Novakov Mikic A . Endocan is useful biomarker of survival and severity in sepsis. Microvasc Res. 2014; 93:92-7. DOI: 10.1016/j.mvr.2014.04.004. View

Poon P, Ng J, Fung W, Chow K, Kwan B, Kam-Tao Li P . Relationship between Plasma Endocan Level and Clinical Outcome of Chinese Peritoneal Dialysis Patients. Kidney Blood Press Res. 2019; 44(5):1259-1270. DOI: 10.1159/000502961. View

Yilmaz M, Siriopol D, Saglam M, Kurt Y, Unal H, Eyileten T . Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014; 86(6):1213-20. DOI: 10.1038/ki.2014.227. View

Qiu C, Fu Q, Sui J, Zhang Q, Wei P, Wu Y . Serum Endothelial Cell-Specific Molecule 1 (Endocan) Levels in Patients With Acute Myocardial Infarction and Its Clinical Significance. Angiology. 2016; 68(4):354-359. DOI: 10.1177/0003319716651349. View

Zhao T, Kecheng Y, Zhao X, Hu X, Zhu J, Wang Y . The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: A meta-analysis. Medicine (Baltimore). 2018; 97(49):e13407. PMC: 6310565. DOI: 10.1097/MD.0000000000013407. View

Pauly D, Hamed S, Behnes M, Lepiorz D, Lang S, Akin I . Endothelial cell-specific molecule-1/endocan: Diagnostic and prognostic value in patients suffering from severe sepsis and septic shock. J Crit Care. 2015; 31(1):68-75. DOI: 10.1016/j.jcrc.2015.09.019. View

Su Y, Shu K, Hu C, Cheng C, Wu M, Yu T . Serum Endocan correlated with stage of chronic kidney disease and deterioration in renal transplant recipients. Transplant Proc. 2014; 46(2):323-7. DOI: 10.1016/j.transproceed.2013.10.057. View

Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C . Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2005; 1765(1):25-37. DOI: 10.1016/j.bbcan.2005.08.004. View

McMillan R, Skiadopoulos L, Hoppensteadt D, Guler N, Bansal V, Parasuraman R . Biomarkers of Endothelial, Renal, and Platelet Dysfunction in Stage 5 Chronic Kidney Disease Hemodialysis Patients With Heart Failure. Clin Appl Thromb Hemost. 2017; 24(2):235-240. PMC: 6707716. DOI: 10.1177/1076029617729216. View

10.

Samouilidou E, Bountou E, Papandroulaki F, Papamanolis M, Papakostas D, Grapsa E . Serum Endocan Levels are Associated With Paraoxonase 1 Concentration in Patients With Chronic Kidney Disease. Ther Apher Dial. 2018; 22(4):325-331. DOI: 10.1111/1744-9987.12654. View

11.

Lee Y, Shin Y, Lee S, Kim Y, Lee S, Moon J . Effects of online hemodiafiltration on anemia and nutritional status in chronic hemodialysis patients. Kidney Res Clin Pract. 2020; 39(1):103-111. PMC: 7105619. DOI: 10.23876/j.krcp.19.082. View

12.

Pawlak K, Mysliwiec M, Pawlak D . Endocan--the new endothelial activation marker independently associated with soluble endothelial adhesion molecules in uraemic patients with cardiovascular disease. Clin Biochem. 2015; 48(6):425-30. DOI: 10.1016/j.clinbiochem.2015.01.006. View

13.

Foley R, Parfrey P, Sarnak M . Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32(5 Suppl 3):S112-9. DOI: 10.1053/ajkd.1998.v32.pm9820470. View

14.

Lee Y, Kim J, Kim S, Kim Y, Moon J, Jeong K . Plasma endocan level and prognosis of immunoglobulin A nephropathy. Kidney Res Clin Pract. 2016; 35(3):152-9. PMC: 5025467. DOI: 10.1016/j.krcp.2016.07.001. View

15.

Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent J, Nicolis I . Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005; 82(4):777-83. DOI: 10.1093/ajcn/82.4.777. View

16.

Gunay M, Mertoglu C . Increase of endocan, a new marker for inflammation and endothelial dysfunction, in acute kidney injury. North Clin Istanb. 2019; 6(2):124-128. PMC: 6593909. DOI: 10.14744/nci.2018.70446. View

17.

Scherpereel A, Gentina T, Grigoriu B, Senechal S, Janin A, Tsicopoulos A . Overexpression of endocan induces tumor formation. Cancer Res. 2003; 63(18):6084-9. View

18.

Hwang H, Kim J, Kim Y, Lee S, Ahn S, Lee H . Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients. J Clin Med. 2020; 9(1). PMC: 7019341. DOI: 10.3390/jcm9010244. View

19.

Lee Y, Kim S, Moon H, Seo J, Kim D, Park S . Endocan as a marker of microvascular inflammation in kidney transplant recipients. Sci Rep. 2019; 9(1):1854. PMC: 6372712. DOI: 10.1038/s41598-018-37975-9. View

20.

Santoro A, Mancini E . Cardiac effects of chronic inflammation in dialysis patients. Nephrol Dial Transplant. 2002; 17 Suppl 8:10-5. DOI: 10.1093/ndt/17.suppl_8.10. View